Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
BMY
Bristol-Myers Squibb Company
RayzeBio introduces radiopharmaceuticals, a direct product/technology category.
|
$126.89B |
$61.06
-2.03%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$121.25B |
$472.44
-1.14%
|
|
CVS
CVS Health Corporation
CVS administers vaccines across its pharmacy network, a direct service offering.
|
$102.28B |
$79.62
-1.18%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$82.77B |
$776.52
-1.39%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$56.92B |
$17.77
-2.47%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$55.51B |
$125.30
-0.52%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$53.03B |
$218.01
-2.32%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$51.80B |
$633.17
-2.39%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$48.95B |
$169.04
-1.43%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$47.81B |
$10.22
-2.34%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$45.75B |
$735.59
-1.86%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$43.24B |
$327.78
+0.15%
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$41.39B |
$82.83
-1.71%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare markets proprietary radiopharmaceuticals (e.g., Flyrcado) and radiopharmaceutical diagnostics.
|
$36.00B |
$77.40
-2.05%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$34.85B |
$18.00
-1.07%
|
|
A
Agilent Technologies, Inc.
BIOVECTRA acquisition expands Agilent's contract manufacturing capabilities (CDMO) for advanced modalities.
|
$34.17B |
$119.40
-0.95%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$33.12B |
$296.92
-0.70%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$31.97B |
$147.06
-1.88%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$30.24B |
$179.47
+0.89%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$27.86B |
$188.99
-0.50%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$27.26B |
$253.28
-0.75%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$24.95B |
$103.02
-0.76%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$23.28B |
$277.19
-1.30%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$22.58B |
$58.01
+0.36%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$21.11B |
$481.38
-1.80%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$20.53B |
$29.12
-1.36%
|
|
IFF
International Flavors & Fragrances Inc.
IFF's probiotic and digestive health offerings align with digestive health OTC products.
|
$20.02B |
$78.37
+0.23%
|
Showing page 2 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
